These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 34938300)

  • 1. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
    Nielsen DL; Juhl CB; Nielsen OH; Chen IM; Herrmann J
    JAMA Oncol; 2024 Oct; 10(10):1390-1399. PubMed ID: 39172480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.
    Gradone AL; Ma VT; Vasbinder A; Fecher LA; Yentz S; Hayek SS; Lao CD
    Cancer Immunol Immunother; 2024 Oct; 73(12):259. PubMed ID: 39369180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
    Hu X; Wei Y; Shuai X
    Front Immunol; 2021; 12():799077. PubMed ID: 34975911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature.
    Nakagomi Y; Tajiri K; Shimada S; Li S; Inoue K; Murakata Y; Murata M; Sakai S; Sato K; Ieda M
    Front Pharmacol; 2022; 13():884776. PubMed ID: 35645839
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
    Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.
    Cavalcante L; Chandana S; Lakhani N; Enstrom A; LeBlanc H; Schmalz J; Lengyel K; Schneider F; Thomas H; Chisamore MJ; Peng SL; Naumovski A; Davar D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39142718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
    Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
    Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
    Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
    Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
    Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
    J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-induced Myositis.
    Jayan A; Mammen AL; Suarez-Almazor ME
    Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.